• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Longeveron Inc. - Class A Common stock (NQ:LGVN)

6.580 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
August 25, 2026
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
August 25, 2026
Via Chartmill
Which stocks are moving after the closing bell on Monday? ↗
August 24, 2026
Via Chartmill
News headline image
Longeveron (LGVN) Q2 2026 Earnings Call Transcript ↗
August 19, 2026
ELPIS II trial data expected September 2026 as cash runway extends into Q4. 
Via The Motley Fool
Topics Earnings Intellectual Property
Longeveron Inc. (NASDAQ:LGVN) Reports Q4 2025 Earnings Beat and Updates Lomecel-B Timeline ↗
March 17, 2026
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 4, 2025 ↗
November 04, 2025
 
Via Benzinga
News headline image
Longeveron (LGVN) Q1 2026 Earnings Transcript ↗
May 13, 2026
Longeveron (LGVN) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
April 23, 2026
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met 
From Equity Insider
Via GlobeNewswire
News headline image
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
March 18, 2026
AVAI, FBLG, FATE, MESO, and LGVN as Regenerative Medicine Moves From Lab to GMP Manufacturing Facilities 
From USA News Group
Via GlobeNewswire
News headline image
Longeveron (LGVN) Q4 2025 Earnings Call Transcript ↗
March 18, 2026
Longeveron (LGVN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Preview For Longeveron ↗
November 03, 2025
 
Via Benzinga
In today's session, these stocks are experiencing unusual volume. ↗
March 16, 2026
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
March 16, 2026
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
March 13, 2026
Via Chartmill
Which stocks have an unusual volume on Friday? ↗
March 13, 2026
Via Chartmill
Which stocks are moving on Tuesday? ↗
March 10, 2026
Via Chartmill
News headline image
Preview: Longeveron's Earnings ↗
August 12, 2025
 
Via Benzinga
Curious about the most active stocks on Tuesday? ↗
March 10, 2026
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
March 10, 2026
Via Chartmill
Gapping stocks in Tuesday's session ↗
March 10, 2026
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
March 10, 2026
Via Chartmill
News headline image
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty In Study ↗
February 25, 2026
Longeveron said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
November 04, 2025
 
Via Benzinga
News headline image
These stocks have an unusual volume in today's session ↗
August 14, 2025
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill
News headline image
Longeveron Posts 32% Revenue Drop in Q2 ↗
August 13, 2025
Via The Motley Fool
News headline image
Longeveron Inc. (NASDAQ:LGVN) Q2 2025 Earnings: Revenue Misses, EPS Narrower Than Expected ↗
August 13, 2025
Longeveron Inc. (LGVN) reported Q2 2025 earnings with revenue missing estimates at $320K but a narrower EPS loss of $0.33. Stock fell 3.5% post-earnings amid clinical progress in HLHS and Alzheimer's... 
Via Chartmill
News headline image
Top stock movements in today's session. ↗
August 08, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
August 05, 2025
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
August 04, 2025
 
Via Benzinga
News headline image
Earnings Scheduled For August 13, 2025 ↗
August 13, 2025
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap